Experimental group:Administer vericiguat (starting at 5 mg/day and titrating to 10 mg/day or the maximum tolerated dose).

2 trials

Sponsors

Fuwai Hospital, Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences Fuwai Hospital

Conditions

Cardiac AmyloidosisHeart Failure and Low Blood Pressure

Phase 4

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vericiguat in Hospitalized Patients with Heart Failure and Low Blood Pressure

Active, not recruitingChiCTR2600125254

Chinese Academy of Medical Sciences Fuwai HospitalHeart Failure and Low Blood Pressure

Start: 2026-06-01Updated: 2026-05-25

Unknown Phase

Evaluation of the Efficacy and safety of Vericiguat therapy in Patients with Cardiac Amyloidosis: A Randomized, Double-Blind, Placebo-Controlled study

Active, not recruitingChiCTR2600119371

Fuwai Hospital, Chinese Academy of Medical SciencesCardiac Amyloidosis

Start: 2026-03-03Updated: 2026-03-02